Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study
Diabetes/Metabolism Research and Reviews · 2026-01 · 42 (1)
DOI: 10.1002/dmrr.70121 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 10.01.2026. Verfasst von Joshua Stokar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hadassah Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Fatty Liver, Menopause, Non-alcoholic Fatty Liver Disease, Menopause, Premature. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hadassah Medical Organisation, Israel Science Foundation, Hadassah Medical Organization.
Abstract (Originalsprache)
Objectives
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing public health concern that contributes to liver and cardiovascular complications. The prevalence of MASLD in women increases sharply around age 50 years, but the relationship between an earlier age at natural menopause and MASLD is unknown.
Methods
Using the TriNetX global federated network, we identified women with earlier menopause (< 50 years). The control cohort consisted of similarly aged pre‐menopausal women. Cases of premature (< 40 years) or surgical menopause, non‐MASLD causes of steatotic liver disease (SLD), or sex‐hormone therapy were excluded. Propensity‐score matching adjusted for baseline characteristics and metabolic risk factors, resulting in two matched cohorts of 20,979 women (total n = 41,958) in the final analysis. Outcomes included new diagnoses of MASLD (metabolic dysfunction‐associated steatohepatitis) and the MASLD metabolic factors: pre‐diabetes/diabetes, hypertension, dyslipidaemia, and overweight/obesity over 5 years of follow‐up.
Results
Earlier menopause was associated with an increased risk of developing MASLD (HR 1.322, 95% CI 1.170–1.492), new‐onset dyslipidaemia (1.083; 1.045–1.122) and pre‐diabetes (1.130; 1.060–1.205). Findings were consistent across stratified analyses by pre‐existing metabolic risk factors (HR 95% CI for MASLD with pre‐existing dysglycaemia 1.370, 1.042–1.800; dyslipidaemia 1.340, 1.053–1.705; hypertension 1.230, 0.998–1.516; overweight 1.280, 1.086–1.510).
Conclusions
Risk of MASLD is increased following menopause before age 50. Further studies should assess the incorporation of menopause timing into female‐specific cardiometabolic risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Hadassah Medical Center, Jerusalem, Israel.
- Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
ORCID-Profile: Joshua Stokar, Rivka Dresner-Pollak
Förderung
- Hadassah Medical Organisation
- Israel Science Foundation
- Hadassah Medical Organization
Zitieren
APA
Stokar, J., & Dresner-Pollak, R. (2026). Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study. Diabetes/Metabolism Research and Reviews, 42(1). https://doi.org/10.1002/dmrr.70121
Vancouver
Stokar J, Dresner-Pollak R. Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study. Diabetes/Metabolism Research and Reviews. 2026;42(1). doi:10.1002/dmrr.70121
BibTeX
@article{Stokar2026,
author = {Stokar, Joshua and Dresner-Pollak, Rivka},
title = {Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
volume = {42},
number = {1},
doi = {10.1002/dmrr.70121}
}
EUVIMED